RÉSUMÉ
The immunodominant B13 protein of Trypanosoma cruzi is found on the surface of trypomastigotes and exhibits cross-reactivity with the human cardiac myosin heavy chain; for which antibodies against this parasitic antigen may be involved in the development of disease pathology. In a cohort of chronically T. cruzi-infected adults, undergoing trypanocidal treatment, or not, we, therefore, decided to evaluate the levels of anti-B13 antibodies (ELISA-B13) and its eventual relationship with heart complaints. Two hundred twenty-eight serum samples from 76 chronically infected adults with an average follow-up of 24 years were analyzed. Thirty of them had received trypanocidal treatment. Among treated patients, anti-B13 Ab levels in successive samples showed a significant decrease in reactivity as the years after treatment increased (ANOVA test, p = 0.0049). At the end of the follow-up, 36.7% became non-reactive for ELISA B13. Untreated patients did not have significant variations in the level of anti-B13 antibodies during follow-up. None of the treated patients had electrocardiographic changes compatible with chronic chagasic cardiomyopathy, whereas 21.7% of those undergoing no treatment did show such kind of pathological electrocardiogram tracings. ELISA-B13 was reactive in all cases with heart involvement. Among untreated patients, there were no significant differences in anti-B13 antibodies when comparing individuals without proven pathology with those with chronic chagasic cardiomyopathy. Although treatment with trypanocidal drugs was followed by decreased anti-B13 antibody levels, such assessment was unhelpful in differentiating the evolution of chronic chagasic heart disease.
Sujet(s)
Anticorps antiprotozoaires/sang , Antigènes de protozoaire/immunologie , Maladie de Chagas/traitement médicamenteux , Maladie de Chagas/immunologie , Trypanocides/usage thérapeutique , Adulte , Animaux , Argentine , Maladie chronique , Réactions croisées , Test ELISA , Femelle , Études de suivi , Humains , Mâle , Nifurtimox/usage thérapeutique , Nitroimidazoles/usage thérapeutique , Études rétrospectives , Trypanosoma cruzi , Jeune adulteRÉSUMÉ
Los objetivos de este trabajo fueron evaluar el seguimiento de hijos de mujeres infectadas por Trypanosoma cruzi en los Centros de Atención Primaria (CAPS) e identificar las barreras para la detección precoz de Chagas connatal y de infecciones crónicas. Mediante un estudio descriptivo se evaluó el seguimiento de los hijos de mujeres infectadas. Se usaron los sistemas informáticos SISA y SICAP para identificar las mujeres embarazadas infectadas y los CAPS de referencia. Se coordinó con profesionales de los CAPS para evaluar el seguimiento de los hijos y, con la maternidad del Hospital Cullen para informar los nacimientos, realizar control clínico y recabar datos para los controles posteriores. Para relevar las dificultades que limitan el diagnóstico y tratamiento temprano, se utilizó un método de tipo exploratorio a través de encuestas online e implementación de talleres al personal de los CAPS. Se visitaron 10 CAPS a los cuales concurrieron 17 madres y 44 hijos. Tenían diagnóstico en el CAPS, 25/44 (56,8%) hijos: 22 con serología (-) para Chagas luego de los 10 meses de vida y; 2 niños estaban infectados con T. cruzi y fueron tratados con benznidazol. Una niña de 6 meses fue tratada sin confirmar infección. No tenían control en los CAPS, 19 niños: 17 tuvieron serología (-), edad promedio 7±5,8 y; 2 niñas de 3 y 7 años fueron seropositivas, ytratadas con nifurtimox.Nacieron 22 hijos de madres infectadas 100% tuvo microstrout (-) previo al egreso de la maternidad. De los 10 niños mayores al año de vida 6 fueron (-) y 4 no se localizaron. El personal de los CAPS expresó necesidad de capacitación; ausencia de articulación entre especialidades médicas; poca experiencia en relación al tratamiento en crónicos; escasa búsqueda de casos. Se desarrollaron 13 talleres con la participación activa de 83 integrantes de los CAPS. Toda la información se compartió con el Programa Provincial de Chagas. Se enfatiza la necesidad de la formación continua como estrategia de prevención
Sujet(s)
Thérapeutique , Maladie de Chagas , DiagnosticRÉSUMÉ
With the control of the vectorial and transfusional routes of infection with Trypanosoma cruzi, congenital transmission has become an important source of new cases. This study evaluated the efficacy of trypanocidal therapy to prevent congenital Chagas disease and compared the clinical and serological evolution between treated and untreated infected mothers. We conducted a multicenter, observational study on a cohort of mothers infected with T. cruzi, with and without trypanocidal treatment before pregnancy. Their children were studied to detect congenital infection. Among 354 "chronically infected mother-biological child" pairs, 132 were treated women and 222 were untreated women. Among the children born to untreated women, we detected 34 infected with T. cruzi (15.3%), whose only antecedent was maternal infection. Among the 132 children of previously treated women, no infection with T. cruzi was found (0.0%) (p<0.05). Among 117 mothers with clinical and serological follow up, 71 had been treated and 46 were untreated. The women were grouped into three groups. Group A: 25 treated before 15 years of age; Group B: 46 treated at 15 or more years of age; Group C: untreated, average age of 29.2 ± 6.2 years at study entry. Follow-up for Groups A, B and C was 16.3 ± 5.8, 17.5 ± 9.2 and 18.6 ± 8.6 years respectively. Negative seroconversion: Group A, 64.0% (16/25); Group B, 32.6% (15/46); Group C, no seronegativity was observed. Clinical electrocardiographic alterations compatible with chagasic cardiomyopathy: Group A 0.0% (0/25); B 2.2% (1/46) and C 15.2% (7/46). The trypanocidal treatment of women with chronic Chagas infection was effective in preventing the congenital transmission of Trypanosoma cruzi to their children; it had also a protective effect on the women's clinical evolution and deparasitation could be demonstrated in many treated women after over 10 years of follow up.
Sujet(s)
Maladie de Chagas/traitement médicamenteux , Maladie de Chagas/prévention et contrôle , Transmission verticale de maladie infectieuse/prévention et contrôle , Complications parasitaires de la grossesse/traitement médicamenteux , Trypanocides/usage thérapeutique , Trypanosoma cruzi , Adolescent , Adulte , Maladie de Chagas/congénital , Maladie de Chagas/immunologie , Enfant , Enfant d'âge préscolaire , Femelle , Humains , Nourrisson , Nouveau-né , Grossesse , Complications parasitaires de la grossesse/immunologie , Études rétrospectives , Jeune adulteRÉSUMÉ
This work compared the time at which negative seroconversion was detected by conventional serology (CS) and by the ELISA-F29 test on a cohort of chronic chagasic patients treated with nifurtimox or benznidazole. A retrospective study was performed using preserved serum from 66 asymptomatic chagasic adults under clinical supervision, and bi-annual serological examinations over a mean follow-up of 23 years. Twenty nine patients received trypanocide treatment and 37 remained untreated. The ELISA-F29 test used a recombinant antigen which was obtained by expressing the Trypanosoma cruzi flagellar calcium-binding protein gene in Escherichia coli. Among the untreated patients, 36 maintained CS titers. One patient showed a doubtful serology in some check-ups. ELISA-F29 showed constant reactivity in 35 out of 37 patients and was negative for the patient with fluctuating CS. The treated patients were divided into three groups according to the CS titers: in 13 they became negative; in 12 they decreased and in four they remained unchanged. ELISA-F29 was negative for the first two groups. The time at which negativization was detected was significantly lower for the ELISA-F29 test than for CS, 14.5 ± 5.7 and 22 ± 4.9 years respectively. Negative seroconversion was observed in treated patients only. The results obtained confirm that the ELISA-F29 test is useful as an early indicator of negative seroconversion in treated chronic patients.
Sujet(s)
Maladie de Chagas/traitement médicamenteux , Test ELISA/méthodes , Nifurtimox/usage thérapeutique , Nitroimidazoles/usage thérapeutique , Trypanocides/usage thérapeutique , Trypanosoma cruzi/immunologie , Adolescent , Adulte , Anticorps antiprotozoaires/sang , Antigènes de protozoaire/immunologie , Études cas-témoins , Maladie de Chagas/parasitologie , Maladie chronique , Études de cohortes , Femelle , Humains , Mâle , Adulte d'âge moyen , Études rétrospectives , Facteurs temps , Résultat thérapeutique , Jeune adulteRÉSUMÉ
This work compared the time at which negative seroconversion was detected by conventional serology (CS) and by the ELISA-F29 test on a cohort of chronic chagasic patients treated with nifurtimox or benznidazole. A retrospective study was performed using preserved serum from 66 asymptomatic chagasic adults under clinical supervision, and bi-annual serological examinations over a mean follow-up of 23 years. Twenty nine patients received trypanocide treatment and 37 remained untreated. The ELISA-F29 test used a recombinant antigen which was obtained by expressing the Trypanosoma cruzi flagellar calcium-binding protein gene in Escherichia coli. Among the untreated patients, 36 maintained CS titers. One patient showed a doubtful serology in some check-ups. ELISA-F29 showed constant reactivity in 35 out of 37 patients and was negative for the patient with fluctuating CS. The treated patients were divided into three groups according to the CS titers: in 13 they became negative; in 12 they decreased and in four they remained unchanged. ELISA-F29 was negative for the first two groups. The time at which negativization was detected was significantly lower for the ELISA-F29 test than for CS, 14.5 ± 5.7 and 22 ± 4.9 years respectively. Negative seroconversion was observed in treated patients only. The results obtained confirm that the ELISA-F29 test is useful as an early indicator of negative seroconversion in treated chronic patients.
Este trabalho comparou os tempos de soroconversão negativos obtidos pela sorologia convencional (CS) e teste ELISA-F29 em uma coorte de pacientes chagásicos crônicos tratados com nifurtimox ou benznidazol. Um estudo retrospectivo foi realizado com soro preservado de 66 adultos chagásicos assintomáticos com acompanhamento clínico e sorológico semestral ao longo de um seguimento médio de 23 anos. 29 pacientes receberam tratamento tripanossomicida e 37 outras permaneceram sem tratamento. O teste ELISA-F29 usou um antígeno recombinante obtido por expressão do gene de uma proteína flagelar de Trypanosoma cruzi de ligação de cálcio em Escherichia coli. Entre os pacientes não tratados, 36 mantiveram os títulos da CS. Um paciente apresentou sorologia duvidosa em alguns controles. ELISA-F29 apresentou reatividade constante em 35/37 e foi negativo no paciente com CS flutuante. Os pacientes tratados foram agrupados de acordo com os títulos da CS, em três grupos: 13 tornaram-se negativos, 12 diminuíram e quatro permaneceram inalterados. ELISA-F29 foi negativo nos dois primeiros grupos. O tempo de negativização foi significativamente menor para o teste ELISA-F29 do que para CS (14,5 ± 5,7 e 22 ± 4,9 anos, respectivamente). A soroconversão negativa foi observada somente nos pacientes tratados. Os resultados obtidos confirmam que o teste ELISA-F29 é útil como um indicador precoce de soronegativação em pacientes crônicos tratados.
Sujet(s)
Adolescent , Adulte , Femelle , Humains , Mâle , Adulte d'âge moyen , Jeune adulte , Maladie de Chagas/traitement médicamenteux , Test ELISA/méthodes , Nifurtimox/usage thérapeutique , Nitroimidazoles/usage thérapeutique , Trypanocides/usage thérapeutique , Trypanosoma cruzi/immunologie , Anticorps antiprotozoaires/sang , Antigènes de protozoaire/immunologie , Études cas-témoins , Maladie chronique , Études de cohortes , Maladie de Chagas/parasitologie , Études rétrospectives , Facteurs temps , Résultat thérapeutiqueRÉSUMÉ
We investigated the relationship between potentially pathogenic antibodies against a Trypanosoma cruzi ribosomal protein (P2ß) and the evolution of Chagas disease and the effect of trypanocidal treatment on these variables. Seventy-eight patients with chronic Chagas disease who were followed-up for more than 20 years were divided into three groups: 30 asymptomatic persons undergoing specific treatment (group A), 37 asymptomatic persons not undergoing specific treatment (group B), and 11 patients with chronic chagasic cardiomyopathy (CCC) who were not treated. Five patients in group B showed evolution to myocardial abnormalities. Among persons with CCC, six showed no changes; the remaining persons showed progression of cardiac involvement. Levels of antibodies to P2ß in persons in group A decreased from their initial values. This finding was not observed in persons in groups B and C. Comparisons at the end of the follow-up showed lower amounts of antibodies to P2ß in groups A and C. These findings support the benefits of specific treatment during chronic infection.